ClinConnect ClinConnect Logo
Search / Trial NCT05051917

The Italian Coronary Artery Aneurysm and Ectasia In Patients With Acute Coronary Syndrome

Launched by FEDERICO II UNIVERSITY · Sep 15, 2021

Trial Information

Current as of June 28, 2025

Recruiting

Keywords

Aute Coronary Syndrome Coronary Artery Artery Ectasia

ClinConnect Summary

The ITACA study is a research project looking at patients who have Acute Coronary Syndrome (ACS), a serious heart condition, and also have coronary aneurysms or ectasia, which are balloon-like bulges in the arteries. This study aims to gather information about these conditions to better understand how they affect patients with ACS. The trial is currently recruiting participants who are at least 18 years old and have been diagnosed with ACS, along with evidence of these specific heart issues.

To take part in the study, patients need to give their consent and meet certain health criteria. Unfortunately, those who cannot take certain medications, have severe bleeding, or have a life expectancy of less than a year will not be eligible. Participants can expect to be closely monitored during the study, and their experiences will help improve future treatments for others facing similar heart problems. It’s important to know that this study is observational, meaning it will track patients’ health without changing their current treatment plans.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signature of informed consent;
  • Patients aged ≥18 years;
  • diagnosis of ACS (ST-elevation myocardial infarction, non ST-elevation myocardial infarction, unstable angina), in accordance with the definition provided in the latest guidelines;
  • diagnosis of ectasia or coronary aneurysm according to the definitions contained in this protocol, either in the culprit vessel of the SCA than in another vessel. Coronary pseudoaneurysms are excluded.
  • Exclusion Criteria:
  • impossibility or unwillingness to provide signed informed consent;
  • contraindications to dual antiplatelet therapy;
  • contraindications to anticoagulant therapy;
  • active bleeding or severe anemia (Hb \<6 g / dl);
  • life expectancy \<12 months;
  • female patients with potential pregnancy;

About Federico Ii University

Federico II University, located in Naples, Italy, is a prestigious academic institution with a strong emphasis on advanced research and clinical innovation. As a clinical trial sponsor, the university is committed to fostering the development of novel therapeutic interventions and enhancing patient care through rigorous scientific inquiry. With a multidisciplinary approach, Federico II University collaborates with healthcare professionals, researchers, and industry partners to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Its dedication to improving health outcomes is reflected in its robust research programs and commitment to translating scientific findings into clinical practice.

Locations

Naples, , Italy

Forlì, Fc, Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials